
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an o... Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.033 | -10.4430379747 | 0.316 | 0.323 | 0.28 | 713267 | 0.30400541 | CS |
4 | -0.0426 | -13.0835380835 | 0.3256 | 0.36 | 0.222301 | 1830766 | 0.29893627 | CS |
12 | -0.187 | -39.7872340426 | 0.47 | 0.4899 | 0.222301 | 1161884 | 0.32412514 | CS |
26 | -0.867 | -75.3913043478 | 1.15 | 1.29 | 0.222301 | 4190968 | 0.55856621 | CS |
52 | -1.937 | -87.2522522523 | 2.22 | 3.44 | 0.222301 | 2710470 | 0.60270092 | CS |
156 | -1.527 | -84.364640884 | 1.81 | 6.2686 | 0.222301 | 1030041 | 0.82949874 | CS |
260 | -11.867 | -97.670781893 | 12.15 | 13.8 | 0.222301 | 851931 | 0.94523871 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.